Topadur Pharma

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

‍

Download Document Dokument herunterladen

10.9.20

Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

20.6.22

News

Scientific Publication in Advanced Therapeutics

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.

4.4.23

Press Release

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR starts clinical development of a new wound healing drug

Scientific Publication in Advanced Therapeutics

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

Contact

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR starts clinical development of a new wound healing drug

Scientific Publication in Advanced Therapeutics

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

About us

Approach

Disease Areas

Investors

Contact